Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Stochastic and low-scaling techniques: general discussion
Ali Alavi, Marcus T. Allen, Kemal Atalar, Timothy C. Berkelbach, George H. Booth, Hugh G. A. Burton, Garnet Kin‐Lic Chan, Luca Craciunescu, Don Danilov, Werner Dobrautz, Francesco A. Evangelista, Maria-Andreea Filip, Emmanuel Giner, Gabriel Greene‐Diniz, Andreas Grüneis, Yang Guo, Gaurav Harsha, Basil Ibrahim, Venkat Kapil, Daniel Kats, Peter J. Knowles, Marie-Bernadette Lepetit, Ke Liao, Giovanni Li Manni, Pierre‐François Loos, E. A. Magnusson, Antoine Marie, Carlos Mejuto-Zaera, Frank Neese, Arman Nejad, Verena A. Neufeld, Katarzyna Pernal, Felix Plasser, Andrew W. Prentice, Visagan Ravindran, Umatur Rehman, Markus Reiher, Christian Schilling, Gustavo E. Scuseria, James Shee, Benjamin X. Shi, Kalman Szenes, David P. Tew, Alex J. W. Thom, Zikuan Wang, Dominika Zgid, Andrew X. Zhu, Martijn A. Zwijnenburg (2024). Stochastic and low-scaling techniques: general discussion. Faraday Discussions, DOI: 10.1039/d4fd90042a.
Article283 days agoYAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression
Julien Fitamant, Filippos Kottakis, Samira Benhamouche, Helen S. Tian, Nicolas Chuvin, Christine A. Parachoniak, Julia M. Nagle, Rushika M. Perera, Marjorie Lapouge, Vikram Deshpande, Andrew X. Zhu, Albert Lai, Bosun Min, Yujin Hoshida, Joseph Avruch, Daniela Sia, Genís Campreciós, Andrea I. McClatchey, Josep M. Llovet, Dylan Morrissey, Lakshmi Raj, Nabeel Bardeesy (2015). YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Reports, 10(10), pp. 1692-1707, DOI: 10.1016/j.celrep.2015.02.027.
Article259 days agoRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
Andrew X. Zhu, RS Finn, Peter R. Galle, Josep M. Llovet, Jan Blanc, Takuji Okusaka, Ian Chau, Paolo Abada, Yanzhi Hsu, Masatoshi Kudo (2018). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). Annals of Oncology, 29, pp. v122-v122, DOI: 10.1093/annonc/mdy208.
Article259 days ago